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Abstract 
Aims/hypothesis Excessive production of reactive oxygen species (ROS) plays a detrimental 
role in the progression of diabetic kidney disease (DKD). Renal oxidative stress activates 
proinflammatory cytokines, chemokines and profibrotic factors in DKD. Increased 
expression of the prooxidant enzyme NADPH oxidase (NOX) 5 in kidneys of diabetic 
individuals has been hypothesised to correlate with renal injury and progression of DKD. 
Since the gene encoding NOX5 is not expressed in the mouse genome, we examined the 
effect of inducible human NOX5 expression in renal cells, selectively in either endothelial 
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cells or vascular smooth muscle cells (VSMCs)/mesangial cells in a model of insulin-
deficient diabetes, the Akita mouse. 
Methods Renal structural injury, including glomerulosclerosis, mesangial expansion and 
extracellular matrix protein accumulation, as well as renal inflammation, ROS formation and 
albuminuria, were examined in the NOX5 transgenic Akita mouse model of DKD. 
Results Expression of NOX5 in either endothelial cells or VSMCs/mesangial cells in diabetic 
Akita mice was associated with increased renal inflammation (monocyte chemoattractant 
protein-1, NF-κB and toll-like receptor-4) and glomerulosclerosis, as well as upregulation of 
protein kinase C-α and increased expression of extracellular matrix genes (encoding collagen 
III, fibronectin and α-smooth muscle actin) and proteins (collagen IV), most likely mediated 
via enhanced renal ROS production. The effect of VSMC/mesangial cell-specific NOX5 
expression resulted in more pronounced renal fibrosis in comparison with endothelial cell-
specific NOX5 expression in diabetic mice. In addition, albuminuria was significantly 
increased in diabetic VEcad+NOX5+  mice (1192±194 µg/24 h) when compared with diabetic 
VEcad+NOX5- mice (770±98 µg/24 h). Furthermore, the regulatory components of NOX5 
activation, including heat shock protein 90 and transient receptor potential cation channel 
subfamily C member 6, were upregulated only in the presence of both NOX5 and diabetes.  
Conclusions/interpretation The findings from this study highlight the importance of NOX5 in 
promoting diabetes-related renal injury and provide the rationale for the development of a 
selective NOX5 inhibitor for the prevention and/or treatment of DKD. 
 
Research in context 
What is already known about this subject?  
• Diabetic kidney disease (DKD) is the leading cause of chronic renal failure requiring 
dialysis or transplantation. 
• Intrarenal oxidative stress plays a critical role in the pathogenesis of DKD. 
• The prooxidant enzyme, NADPH oxidase (NOX) 5, is highly upregulated in the 
kidney of diabetic patientsindividuals. NOX5 is present in humans but not in rats or 
mice and therefore, its role in conventional animal models of DKD has been difficult 
to assess. 
What is the key question?  
• Does selective expression of human NOX5 in endothelial or VSMCs/mesangial cells 
in the Akita mouse accelerate specific manifestations of DKD? 
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What are the new findings?  
• Endothelial cell-specific NOX5 expression primarily exacerbates albuminuria 
whereas VSMC/mesangial cell-specific NOX5 expression aggravates renal fibrosis in 
DKD. 
• Expression of NOX5 in both renal cell populations activates proinflammatory 
pathways. 
How might this impact on clinical practice in the foreseeable future? 
• These findings provide the impetus for the development of a selective NOX5 inhibitor 
for the prevention and/or treatment of DKD. 
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Introduction 
Diabetes is the most common cause of chronic kidney disease, which increases the risk of 
cardiovascular disease leading to premature death [1]. The unique structural arrangement of 
distinct glomerular cell types, including podocytes, endothelial cells and mesangial cells, 
creates a highly specialised microvascular bed: the filtration barrier. Tightly coordinated 
movement and crosstalk between these cell types is required for the formation of a functional 
glomerular filtration barrier which filters blood to form urine [2, 3]. Indeed, failure to 
adequately maintain glomerular barrier function in conditions such as diabetic kidney disease 
(DKD) results in the excretion of critical blood components including albumin into the urine 
[2, 4]. 
The prooxidant enzyme NADPH oxidase (NOX), particularly the NOX4 isoform, generates 
reactive oxygen species (ROS), which contribute to renal pathology in a range of 
experimental models of DKD [5–8]. However, another isoform of NOX, NOX5, has attracted 
increasing attention in the context of human DKD [9–11]. Indeed, previous studies including 
our own have shown increased expression of NOX5 protein in human kidney 
biopsies/nephrectomy samples from diabetic individuals [10, 11]. Importantly, the NOX5 
gene present in humans is absent from the mouse and rat genome and therefore it has been 
difficult to explore the functional importance of this specific isoform in experimental 
diabetes. However, a study in an inducible human transgenic NOX5 mouse model with 
selective expression of NOX5 in podocytes has shown not only podocyte injury but also 
albuminuria and renal inflammation in association with enhanced ROS production, further 
accelerated in the presence of streptozotocin (STZ)-induced diabetes [10].  
Glomerular endothelial and mesangial cells are key components of the filtration barrier and 
damage of these cells at a structural and functional level in diabetes leads to the progression 
of DKD. Thus, in this study, we examined the effect of inducible human NOX5 expression 
either in endothelial cells or in vascular smooth muscle cells (VSMCs; representing 
mesangial cells in the kidney) in transgenic mice, in the presence and absence of diabetes. 
Rather than using a chemical model of insulin-deficient diabetes (i.e. STZ-induced), we 
chose to study transgenic expression of NOX5 in the Akita mouse model, a genetic model of 
insulin-deficient diabetes with more advanced renal fibrosis, inflammation and albuminuria. 
 
Methods  
Animals 
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The Nox5 transgenic mice were generated by our collaborators (A/Prof Christopher Kennedy, 
University of Ottawa, Canada and Prof Rhian Touyz, University of Glasgow, UK)as 
described previously [10, 11]. Briefly, the purified human NOX5β gene coding region was 
ligated with the Tet-responsive promoter Pbi-1 (Clontech, Mountain View, CA, USA) to 
generate the NOX5β founder mouse on the FVB/N background. The SM22-tTA-FVB/N 
mouse and VEcad-tTA-FVB/N mouse strains were generated by introducing the VSMC-
specific promoter transgelin (SM22; encoded by Sm22, also known as Tagln) or the 
endothelial cell-specific promoter vascular endothelial cadherin (VEcad; encoded by VEcad, 
also known as Cdh5) to the tetracycline-regulated transcriptional activator (tTA-Off) gene. 
Subsequently, to generate VSMC- and endothelial cell-specific NOX5 transgenic mice, the 
SM22-tTA-FVB/N strain or VEcad-tTA-FVB/N strain were crossed with the NOX5β FVB/N 
strain to produce either Sm22+NOX5+ and Sm22+NOX5− mice or VEcad+NOX5+ and 
VEcad+NOX5− mice at the animal facility at Monash University. To subsequently generate 
insulin-deficient diabetic Sm22+NOX5+ and Sm22+NOX5− mice or VEcad+NOX5+ and 
VEcad+NOX5− mice, SM22-tTA-FVB/N or VEcad-tTA-FVB/N strains were crossed with 
Akita/NOX5β FVB/N mice. Akita mice were sourced from The Jackson Laboratory (Bar 
Harbor, ME, USA). Six-week-old male, heterozygous Akita mice with and without Nox5 
expression (Sm22+NOX5+ and Sm22+NOX5− or VEcad+NOX5+ and VEcad+NOX5−) were used 
for the start of the study at which time point they had already developed hyperglycaemia. The 
littermates of non-Akita version of Sm22+NOX5+ and Sm22+NOX5− mice or VEcad+NOX5+ 
and VEcad+NOX5− mice were used as non-diabetic controls. All animal studies were 
approved by the Alfred Medical Research & Education Precinct (AMREP) Animal Ethics 
Committee under guidelines laid down by the National Health and Medical Research Council 
of Australia. 
Mice were placed individually into metabolic cages (Iffa Credo, Lyon, France) for 24 h at 15 
weeks of age. Blood glucose, HbA1c and systolic blood pressure were measured, as described 
previously [6, 12]. Urinary albumin concentration was measured by using a mouse albumin 
ELISA quantification kit (Bethyl Laboratories, Montgomery, TX, USA). Urinary and plasma 
creatinine were determined by using the Cobas Integra 400 Plus analyser (Roche Diagnostics, 
Indianapolis, IN, USA). After 10 weeks (at 16 weeks of age), mice were anaesthetised by i.p. 
injection of sodium pentobarbital (100 mg/kg body weight; Euthatal; Sigma-Aldrich, Castle 
Hill, NSW, Australia). As there is no specific intervention and mice develop diabetes 
spontaneously they were not randomised. Only mice with blood glucose levels ≥15 mmol/l 
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have been included in the experiments; mice with blood glucose <15 mmol/l and with 
polycystic kidney were excluded from the study (<5% of the total number of mice).  
 
 
 
Histological assessment of renal pathology 
Paraffin kidney sections (3 μm) were stained with Periodic Acid–Schiff for the measurement 
of mesangial expansion, glomerulosclerotic index (GSI) and tubulointerstitial injury (TII), as 
described previously [6, 11, 13]. Immunostaining for nitrotyrosine (rabbit anti-nitrotyrosine, 
catalogue no. ab5411; Millipore, Billerica, MA, USA), collagen IV (goat anti- type IV 
collagen, catalogue no. 1340-01; Southern Biotech, Birmingham, AL, USA), protein kinase 
C-α (PKC-α) (rabbit polyclonal, catalogue no. sc-208; Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) and toll-like receptor-4 (TLR-4) (rabbit polyclonal, catalogue no. bs-1021R; 
Bioss Antibodies, Woburn, MA, USA) were performed as described previously [6, 11]. 
Mesangial area and quantification of glomerular collagen IV, nitrotyrosine, PKC-α and TLR-
4 were analysed from digital pictures of glomeruli (20 glomeruli per mouse) and tubules (10 
tubulointerstitial fields per mouse for TII) using Image-Pro plus 7.0 software (Media 
Cybernetics, Bethesda, MD, USA). GSI and tubulointerstitial injury were graded, as 
described previously [6, 11, 13]. All assessments were performed in a blinded manner. 
 
Immunofluorescence 
Double immunostaining of mouse frozen kidney sections (5 µm) was performed as described 
previously [11]. Briefly, double staining for either NOX5 and SM22-α or NOX5 and CD31 in 
mouse kidney tissue was performed by incubation with primary antibody to NOX5 (rabbit 
polyclonal, catalogue no. ab191010; Abcam, Cambridge, MA, USA) and SM22-α (goat 
polyclonal, catalogue no. ab10135; Abcam) or CD31 (goat polyclonal, catalogue no. 
AF3628; R&D Systems, Minneapolis, MN, USA), followed by incubation with secondary 
antibody Alexa Fluor 568 (donkey anti-rabbit; Invitrogen, Eugene, OR, USA) and Alexa 
Fluor 488 (donkey anti-goat; Invitrogen). Dihydroethidium (DHE) staining was performed as 
described previously [11]. All stained sections were examined and images were captured 
using a Nikon eclipse-Ni (Tokyo, Japan) fluorescence microscope. 
 
Quantitative RT-PCR 
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Total RNA from the renal cortex was extracted with Trizol and analysed, and cDNA 
generated as described previously [6, 7]. Gene expression using probes and primers as 
described in electronic supplementary material (ESM) Table 1 were analysed quantitatively 
and reported relative to the expression of the housekeeping gene 18S (18S ribosomal RNA 
Taqman Control Reagent kit) using the Taqman system (ABI Prism 7500; Perkin-Elmer, 
Poster City, CA, USA) [6, 12]. Results were expressed relative to respective non-diabetic 
Sm22+NOX5− mice or VEcad+NOX5− mice, which were arbitrarily assigned a value of 1. 
 
Western blot 
Western blot analysis of frozen kidney was performed as described previously [11]. Briefly, 
protein extracts from the renal cortex were electrophoresed on 7.5–10% acrylamide gels 
under non-reducing conditions. Western blot analysis was then performed after incubation 
with primary antibodies to the following: NOX5 (rabbit polyclonal, catalogue no. ab191010; 
Abcam); nitrotyrosine (rabbit polyclonal, catalogue no. N0409; Sigma-Aldrich-Merck, Castle 
Hill, NSW, Australia), nuclear factor erythroid 2-related factor 2 (NRF2) (goat polyclonal, 
catalogue no. SAB2501713; Sigma-Aldrich-Merck); monocyte chemoattractant protein-1 
(MCP-1) (rabbit polyclonal, catalogue no. ab25124; Abcam); NF-κB-p65 (rabbit polyclonal, 
catalogue no. 51-0500; Invitrogen); TLR-4 (rabbit polyclonal, catalogue no. bs-1021R; Bioss 
Antibodies); PKC-α (rabbit polyclonal, catalogue no. sc-208; Santa Cruz Biotechnology); 
heat shock protein 90 (HSP90) (rat monoclonal, catalogue no. ab13494; Abcam) and transient 
receptor potential cation channel subfamily C member 6 (TRPC-6) (rabbit polyclonal, 
catalogue no. ab62461; Abcam). Blots were then incubated with secondary antibodies as 
follows: goat anti-rabbit for NOX5, nitrotyrosine, MCP-1, NF-κB-p65, TLR-4, PKC-α and 
TRPC-6; rabbit anti-goat for NRF2 and rabbit anti-rat for HSP90 (Dako Corp., Carpinteria, 
CA, USA). Membranes were subsequently probed for β-actin (42 kDa; Sigma-Aldrich) to 
confirm equal loading of samples. Blots were detected using the ECL detection kit (Sigma-
Aldrich) and densitometry was performed using Quantity-One software (Bio-Rad 
Laboratories, Richmond, CA, USA). 
 
Statistical analysis 
All variables were analysed by one-way ANOVA using GraphPad Prism 7 (San Diego, CA, 
USA) for multiple comparison of the means followed by Tukey’s post hoc test or analysed by 
the two-tailed unpaired Mann–Whitney U test when required. A p value <0.05 was 
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considered to be statistically significant. Results are expressed as mean ± SEM, unless 
otherwise specified.  
 
Results 
Characterisation of human NOX5 expression in VSMCs or endothelial cells of 
transgenic mice 
NOX5 protein expression in mesangial cells was confirmed by co-localisation of NOX5 and 
SM22-α (a marker of smooth muscle cells) (Fig. 1a) and in endothelial cells by co-
localisation of NOX5 and CD31 (a marker of endothelial cells) (Fig. 1d) in the glomeruli of 
respective Sm22+NOX5+ and VEcad+NOX5+ transgenic mice. Both Sm22+NOX5+ and 
VEcad+NOX5+diabetic transgenic Akita mice demonstrated increased renal NOX5 protein 
levels when compared with non-diabetic wild-type control mice (Fig.1b,c,e,f). 
 
Metabolic variables 
Both Sm22+NOX5− and Sm22+NOX5+ diabetic Akita mice displayed reduced body weight, 
increased kidney weight/body weight ratio, elevated plasma glucose and HbA1c levels, 
increased food and water intake and enhanced urine output (Table 1) when compared with 
their respective non-diabetic control mice. Similar findings with respect to metabolic 
variables were observed in VEcad+NOX5− and VEcad+NOX5+ Akita diabetic vs non-diabetic 
mice (Table 2). Expression of NOX5 in VSMCs or in endothelial cells had no effect on 
hyperglycaemia-induced changes in these metabolic variables (Tables 1 and 2). In addition, 
systolic blood pressure was similar in all groups (Tables 1 and 2). 
 
Renal oxidative stress 
Expression levels of renal nitrotyrosine (Fig. 2a–d) and intensity of DHE fluorescence (Fig. 
2e) were increased by diabetes in Sm22+NOX5− Akita mice; these diabetes-induced changes 
were more marked in Sm22+NOX5+ diabetic Akita mice. Similar findings were seen in 
endothelial cell-specific NOX5-expressing Akita mice (Fig. 2h–l). Expression of both Nox2 
(also known as Cybb) and Nox4 mRNA were increased in Sm22+NOX5− (Fig. 2f,g) and 
VEcad+NOX5− diabetic Akita mice (Fig. 2m,n). The presence of NOX5, either in VSMCs or 
endothelial cells, did not have any effect on Nox2 mRNA expression in both non-diabetic and 
diabetic mice (Fig. 2f,m); however, downregulation of Nox4 was observed in the presence or 
absence of diabetes in both Sm22+NOX5+ (Fig. 2g) and VEcad+NOX5+ mice (Fig. 2n). 
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NRF2 The expression levels of the key transcription factor linked to antioxidant–redox 
signalling, NRF2, were increased by diabetes alone or by expression of the human NOX5 
gene in both mesangial cells (Fig. 3a,c) and endothelial cells (Fig. 3b,d) of NOX5 transgenic 
mice. The raised mRNA expression levels of Nrf2 (also known as Nfe2l2) in diabetic mice 
were further increased by the expression of NOX5 in these renal cells.  
 
Renal inflammation 
NF-κB and MCP-1 The gene and protein expression of the key proinflammatory 
transcription factor NF-κB (gene also known as Rela) (Fig. 4a–c) and the NF-κB-dependent 
chemokine MCP-1 (gene also known as Ccl2) (Fig. 5a–c) were increased in the renal cortex 
of Sm22+NOX5− diabetic Akita mice. Renal NF-κB and MCP-1 expression was further 
increased in diabetic Akita mice expressing NOX5 in VSMCs/mesangial cells when 
compared with diabetic Akita Sm22+NOX5− mice (Figs 4a–c, 5a–c). In addition, renal 
expression of both NF-κB and MCP-1 were upregulated even in the absence of diabetes in 
Sm22+NOX5+ mice (Figs 4a–c, 5a–c). Similar findings were observed in endothelial cell-
specific NOX5-expressing transgenic Akita mice (Figs 4d–f, 5d–f). 
 
TLR-4 and PKC-α Both TLR-4 and PKC-α have been associated with increased expression 
of MCP-1 via activation of NF-κB and promote renal inflammation in DKD. The expression 
levels of TLR-4 (Fig. 6a–e) and PKC-α (Fig. 7a–e) gene and protein were increased in the 
renal cortex of Sm22+NOX5− diabetic Akita mice and were further increased in diabetic Akita 
mice expressing NOX5 in VSMCs/mesangial cells (Figs 6a–e, 7a–e). In addition, PKC-α 
expression was increased even in the absence of diabetes in Sm22+NOX5+ mice (Fig. 7a–e). 
Similar findings with regards to TLR-4 and PKC-α expression were also observed in 
endothelial cell-specific NOX5-expressing Akita mice (Figs 6f–j, 7f–j). 
 
Renal function (albuminuria and creatinine clearance) 
Increased creatinine clearance was seen in both diabetic groups of Akita mice when 
compared with their respective controls but expression of NOX5 in both VSMCs (Table 1) 
and endothelial cells (Table 2) had no significant effect on creatinine clearance. The effect of 
NOX5 expression per se in both renal cell populations did not increase albuminuria in the 
absence of diabetes. Albuminuria was significantly increased in both groups of diabetic mice 
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when compared with their respective non-diabetic control groups (Table 1). A non-significant 
increase in urinary albumin/creatinine ratio (p=0.057) was observed in diabetic Sm22+NOX5+ 
Akita mice when compared with diabetic Sm22+NOX5− mice (Table 1). In contrast, 
endothelial cell-specific NOX5 expression (VEcad+NOX5+) in the presence of diabetes 
resulted in a twofold increase in both 24 h albuminuria and albumin/creatinine ratio (Table 2) 
when compared with diabetic VEcad+NOX5− Akita mice.  
 
Renal structure (mesangial expansion, glomerulosclerosis and extracellular matrix 
accumulation) 
Diabetic Akita mice showed increased mesangial area, GSI (Fig. 8) and tubulointerstitial 
injury (ESM Fig. 1) when compared with non-diabetic control mice. NOX5 expression in 
VSMCs/mesangial cells further increased mesangial area and glomerulosclerosis in the 
presence of diabetes when compared with diabetic Sm22+NOX5− Akita mice (Fig. 8a–c). 
Findings in endothelial cell-specific NOX5-expressing Akita mice were not statistically 
significant with respect to increases in mesangial area (p=0.06) and glomerulosclerosis 
(p=0.055) (Fig. 8d–f) when compared with diabetic VEcad+NOX5− mice. Furthermore, the 
diabetes-induced increase in tubulointerstitial injury was unchanged by NOX5 expression 
(ESM Fig. 1). 
 
Extracellular matrix gene and protein expression Renal cortical gene expression of 
profibrotic markers, including collagen III, fibronectin and α-smooth muscle actin (α-SMA) 
(Fig. 9a,d), and protein expression of both glomerular and renal cortical collagen IV (Fig. 
9b,c,e,f and ESM Fig. 2) in mice were not altered by expression of NOX5 in the absence of 
diabetes. However, the diabetes-induced increase in the gene expression of collagen III, 
fibronectin and α-SMA was further upregulated in both VSMC- and endothelial cell-specific 
NOX5 transgenic diabetic mice (Fig. 9a,d). Extracellular matrix (ECM) protein expression of 
glomerular collagen IV was further increased in diabetic Sm22+NOX5+ Akita mice when 
compared with diabetic Sm22+NOX5− Akita mice (Fig. 9b,c). In addition, endothelial cell-
specific NOX5 expression caused a non-significant increase in glomerular collagen IV 
accumulation (p=0.056) in the presence of diabetes, as observed when comparing 
VEcad+NOX5+ with VEcad+NOX5− diabetic mice (Fig. 9e,f). 
 
HSP90 and TRPC-6 We examined the regulatory elements of NOX5 including HSP90 and 
TRPC-6 which modulate NOX5 function. Expression of either NOX5 alone in endothelial 
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and VSMCs or diabetes alone had no effect on the protein expression of HSP90 or TRPC-6 in 
Akita mice (Figs 10a–d, 11a–d). Interestingly, expression of NOX5 in VSMCs/mesangial 
cells in the presence of diabetes significantly upregulated the expression of HSP90 (Fig. 
10a,b) and TRPC-6 (Fig. 11a,b) when compared with diabetic Sm22+NOX5− Akita mice. 
Similar patterns were found with regards to HSP90 (p<0.05, Fig. 10c, d) and TRPC-6 
(p=0.06, Fig. 11c,d) expression in endothelial cell-specific NOX5 transgenic diabetic Akita 
mice. 
 
Discussion 
Renal ROS have been shown to play a key role in the activation of proinflammatory 
cytokines, chemokines and profibrotic factors in DKD [6, 7, 11]. In this study we provide 
critical information on directly targeting the source of renal ROS in diabetes by specifically 
exploring the role of the prooxidant enzyme NOX5 in the pathogenesis of DKD. Since 
mesangial and endothelial cells are key components of glomeruli and their structural and 
functional alterations contribute to renal impairment in diabetes, we examined the effect of 
inducible human NOX5 expression either in VSMCs, which represent mesangial cells in the 
kidney, or in endothelial cells in the Akita mouse model of DKD. The key finding of this 
study is that NOX5 expression in these two cell populations in the diabetic Akita mouse leads 
to additive effects on top of hyperglycaemia with regards to accelerated glomerular injury, 
inflammation, fibrosis and albuminuria (Fig. 12).  
We and others have previously demonstrated increased renal expression of NOX5 in 
individuals with diabetes [10, 11]. We demonstrated an upregulation of NOX5 in human 
mesangial cells exposed to glucose in vitro and that silencing of NOX5 attenuated glucose 
induced ROS in association with a decrease in a range of markers of inflammation and 
fibrosis [11]. Consistent with the findings of previous studies [6, 7, 11], diabetic Akita mice 
showed increased levels of ROS, including nitrotyrosine and DHE, in the kidney. NOX5 
expression either in endothelial or in smooth muscle cells did not cause an increase in ROS in 
the absence of diabetes. Diabetes caused an increase in renal ROS and the expression of 
NOX5 in both renal cell populations increased ROS further; this ‘double-hit’ resulted in 
accelerated renal injury. 
With respect to other NOX isoforms, we have previously shown that NOX1 does not play a 
role in DKD [6], deletion of NOX2 in diabetes is not a favourable target because of its role in 
phagocytosis with lethality in the setting of diabetes [14] and NOX4 plays a detrimental role 
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in experimental DKD [5–7, 15]. In the current study, NOX5 expression did not modulate 
NOX2 expression but a downregulation of NOX4 was observed in the NOX5 transgenic mice 
in both diabetic and non-diabetic contexts. These findings are consistent with the further 
increase in renal ROS formation in NOX5 transgenic diabetic mice, most likely occurring as a 
result of concomitant expression of NOX5. This contrasts with a study in which expression of 
NOX5 in podocytes induced podocyte injury and albuminuria even in the absence of diabetes 
[10]. 
Oxidative stress occurs as a result of not only increased ROS formation but also depletion in 
antioxidant defence. NRF2 is an important element in antioxidant defence since it regulates 
the expression of antioxidant proteins that protect against oxidative damage triggered by 
injury and inflammation [16, 17]. A recent study, albeit in the diabetic heart, reported time-
dependent effects of hyperglycaemia on NRF2 expression, as reflected by increased 
expression of NRF2 after 2 months but decreased expression of NRF2 after 5 months of STZ-
induced diabetes in mice [18]. In line with this, we identified increased expression of renal 
NRF2 in diabetic mice after 10 weeks of diabetes and this was further increased by NOX5 
expression. Notably, an upregulation of renal NRF2 was also found in response to expression 
of NOX5 even in the absence of diabetes. These data suggest that NOX5 is involved in the 
regulation of NRF2 and that upregulation of NRF2 may potentially play a compensatory role 
in response to the high levels of ROS accumulation mediated via NOX5 activity at least in 
the early stage of diabetes. This may also explain why NOX5 expression per se is not 
associated with increased ROS levels and renal injury in the absence of diabetes. Thus, only 
the presence of both diabetes and NOX5 expression leads to overwhelming ROS production 
resulting in significant end organ injury. 
Inflammation is considered to be a key pathological feature of DKD [19, 20]. 
Proinflammatory chemokines such as MCP-1 play a key role in promoting macrophage 
infiltration and the transcription factor NF-κB is key in regulating the production of cytokines 
in the setting of diabetes [19, 21]. Indeed, diabetic Akita mice showed increased renal 
expression levels of MCP-1 and NF-κB, compared with non-diabetic mice, and levels were 
further increased by expression of both endothelial cell- and VSMC-specific NOX5. 
Interestingly, expression of NOX5 alone even in the absence of diabetes was able to induce 
the expression of these two proinflammatory molecules in the kidney. These findings are 
consistent with those of previous in vitro studies by our group which showed that knockdown 
of NOX5 in human mesangial cells attenuated the expression of high-glucose-induced 
increased expression of MCP-1 and NF-κB [11]. There is also increasing evidence of a role 
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for toll-like receptors, particularly TLR-4, in macrophage infiltration as observed in DKD 
[22, 23]. Glucose per se upregulates TLR-4 in human renal cells and silencing attenuates 
glucose-induced increases in the expression of various inflammatory mediators including IL-
6 and MCP-1 via inactivation of NF-κB [22]. We observed similar effects in relation to 
increased expression of TLR-4 in the kidney of diabetic Akita mice and further increases in 
the NOX5-expressing Akita mice. Our findings extend the results of a recent study which 
suggested that expression of NOX5 in podocytes of transgenic mice promotes renal 
inflammation via a TLR-4-dependent pathway albeit in an non-diabetic inflammatory model 
[24]. 
Activation of the PKC pathway, particularly with regard to the PKC-α and PKC-β isoforms, 
correlates with oxidative stress and inflammation and plays a key role in DKD [7, 8, 25]. In 
addition, PKC-α and PKC-β [26, 27] directly phosphorylate NOX5 and influence its 
enzymatic activity [28, 29]. Moreover, a downregulation of both PKC-α and PKC-β has been 
seen in NOX5-knockdown human mesangial cells [11]. In this study we observed 
upregulation of renal PKC-α in the presence of either NOX5 expression or diabetes alone and 
which was accelerated in NOX5-expressing diabetic mice. These findings suggest the 
presence of a self-perpetuating vicious cycle with a positive feedback loop among NOX5, 
PKC-α and chronic hyperglycaemia which likely exacerbates renal pathology in diabetes. 
Diabetes leads to alterations in the glomerular filtration barrier including ultrastructural 
damage to the endothelial glycocalyx, endothelial cells and podocytes, leading to albuminuria 
[6, 7, 30]. We report here that diabetic Akita mice displayed increased albuminuria which 
was further increased in the context of concomitant NOX5 expression in endothelial cells, 
supporting the important role of the endothelial cell in the glomerular filtration barrier, a 
phenomenon not seen in non-diabetic mice. This effect was less pronounced when NOX5 
was expressed in VSMCs/mesangial cells in diabetic Akita mice. These findings suggest that 
ROS derived from one cell type in the kidney, either endothelial cells or VSMCs, lead to 
local renal damage primarily in glomeruli but potentially also in the renal cortex, leading to 
functional and structural abnormalities including albuminuria and renal fibrosis. 
Given the importance of mesangial and endothelial cells in the morphological and functional 
manifestations of DKD [31, 32], diabetic Akita mice showed increased mesangial expansion 
and glomerulosclerosis. These structural variables were further increased in diabetic mice 
expressing NOX5 in VSMCs/mesangial cells, with the further increase being statistically 
insignificant in diabetic mice expressing NOX5 in endothelial cells. Consistent with the 
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mesangial expansion and glomerulosclerosis findings, the diabetes-induced increase in 
expression levels of ECM components, including renal collagens, fibronectin and α-SMA, 
was enhanced by NOX5 expression in both VSMCs/mesangial and endothelial cells of 
diabetic mice. Thus, this study provides evidence that NOX5 plays an important role in the 
evolution of structural changes in DKD via activation of ROS-mediated profibrotic/sclerotic 
and proinflammatory pathways in diabetes.  
In addition to renal fibrosis and inflammation, the involvement of key intracellular signalling 
pathways implicated in the regulation of NOX5 activity, including TRPC-6 and HSP90, was 
examined [9, 33–35]. A correlation between NOX-derived ROS and the regulation of Ca2+ 
channels by TRPC-6 has been demonstrated in several studies, including one using a model 
of podocyte injury [36–38]. Moreover, unlike other NOX isoforms, NOX5 requires binding 
of intracellular Ca2+ to its EF-hand regulatory domains for the activation and catalytic 
production of superoxide [39]. Indeed, we observed that expression of human NOX5 in either 
of the renal cell types in the mouse kidney was associated with an upregulation of TRPC-6 
only in the presence of diabetes. This is in line with our previous study showing that silencing 
of NOX5 in human mesangial cells attenuated high-glucose-induced increased expression of 
TRPC-6 [11]. In addition, it has been reported that HSP90 binds to the C-terminus of NOX5 
and is necessary for enzyme stability and superoxide production [33, 35]. Furthermore, long-
term inhibition of HSP90 was associated with reduced expression of NOX5 [34]. In this 
study we have demonstrated that diabetes alone or expression of NOX5 alone in both 
mesangial cells and endothelial cells had no direct effect on the expression of HSP90 in the 
kidney. However, expression of NOX5 in either cell type in the presence of diabetes resulted 
in increased expression of renal HSP90. Thus, the findings from this study suggest that 
TRPC-6 and HSP90 act downstream and upstream of NOX5 and that there is either a positive 
feedback loop or a bidirectional activation pathway between TRPC-6 and NOX5 as well as 
HSP90 and NOX5. Other signalling pathways linked to NOX5, such as Ca2+, may also be 
important, as previously demonstrated by us in NOX5-expressing mice [40]. 
In conclusion, identification of a key role for NOX5 in promoting renal injury in diabetes 
provides the rationale for examining NOX5 in models where this isoform is endogenously 
expressed, including humans and other animals such as rabbits. Our findings also provide the 
impetus to develop NOX5-specific inhibitors. 
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Figure legends 
Fig. 1 Expression of human NOX5 in mouse glomerular cells. NOX5 transgenic mice 
expressing NOX5β either in VSMCs/mesangial cells (Sm22+NOX5+) or in endothelial cells 
(VEcad+NOX5+) in the glomerulus were used. (a, d) Co-localisation of NOX5 (red staining), 
SM22-α (a marker of smooth muscle cells; green staining in a) and CD31 (a marker of 
endothelial cells; green staining in d) in frozen kidney sections of respective control 
Sm22+NOX5+ (a) and VEcad+NOX5+ (d) transgenic mice. Scale bar, 20 μm in all 
photomicrographs. (b, e) Western blots showing expression of NOX5 (86 kDa) in the renal 
cortex of the control and Akita diabetic Sm22+NOX5+ (b) and VEcad+NOX5+ (e) transgenic 
mice; (c, f) quantification of (b) and (e), respectively (n=6/group). β-actin (42 kDa) serves as 
a housekeeping protein. Data are shown as mean ± SEM. †p<0.05 vs respective control 
Sm22+NOX5+ or VEcad+NOX5+ mice mice. C, non-diabetic control mice; D, diabetic mice; 
Tg, transgenic. 
 
Fig. 2 Expression of NOX5 either in VSMCs/mesangial cells (a–e) or in endothelial cells 
(h–l) enhances renal ROS production in Akita diabetic mice. (a, b, h, i) Immunostaining of 
glomerular nitrotyrosine  (a, h) and its quantification (b, i) (n=6–9/group) in control and 
Akita diabetic Sm22+NOX5− and Sm22+NOX5+ or VEcad+NOX5− and VEcad+NOX5+ 
transgenic mice, respectively. (c, d, j, k) Western blots showing the expression of renal 
cortical nitrotyrosine (68 kDa) (c, j) and its quantification (d, k) (n=3/group) in control and 
Akita diabetic Sm22+NOX5− and Sm22+NOX5+ or VEcad+NOX5− and VEcad+NOX5+ 
transgenic mice, respectively.  (e–g, l–n) Immunofluorescence staining for glomerular DHE 
(e, l) and gene expression of Nox2 and Nox4 in the renal cortex (f, g, m, n) of respective 
control and Akita diabetic Sm22+NOX5− and Sm22+NOX5+ or VEcad+NOX5− and 
VEcad+NOX5+ transgenic mice. 18s RNA and β-actin (42 kDa) serve as housekeeping gene 
and protein, respectively. Scale bar, 20 μm in all photomicrographs. Data are shown as mean 
± SEM. *p<0.05 vs respective control Sm22+NOX5− or VEcad+NOX5− mice; †p<0.05 vs 
respective control Sm22+NOX5+ or VEcad+NOX5+ mice; ‡p<0.05 vs respective diabetic 
Sm22+NOX5− or VEcad+NOX5− mice; C, non-diabetic control mice; D, diabetic mice; NT, 
nitrotyrosine 
 
Fig. 3 Expression of NRF2 protein in the kidney. Western blots showing the expression of 
NRF2 (61 kDa) in the renal cortex of the control and Akita diabetic Sm22+NOX5− and 
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Sm22+NOX5+ (a) or VEcad+NOX5− and VEcad+NOX5+ (b) transgenic mice and quantification 
of the respective NRF2 expression levels (c, d) (n=3/group). β-actin (42 kDa) serves as a 
housekeeping protein. Data are shown as mean ± SEM. *p<0.05 vs respective control 
Sm22+NOX5− or VEcad+NOX5− mice; †p<0.05 vs respective control Sm22+NOX5+ or 
VEcad+NOX5+ mice; ‡p<0.05 vs respective diabetic Sm22+NOX5− or VEcad+NOX5− mice; 
¶p=0.06 vs control VEcad+NOX5− mice. C, non-diabetic control mice; D, diabetic mice 
 
Fig. 4 Gene and protein expression of the p65 subunit of NF-κB in the kidney. (a, c, d, f) 
Western blots showing the expression of NF-κB (68 kDa) protein in the renal cortex of the 
respective control and Akita diabetic Sm22+NOX5− and Sm22+NOX5+ (a) or VEcad+NOX5− 
and VEcad+NOX5+ (d) transgenic mice, and quantification of the expression levels (c, f) 
(n=6/group). (b, e) Renal Nfκb mRNA expression in control and Akita diabetic Sm22+NOX5− 
and Sm22+NOX5+ (b) or VEcad+NOX5− and VEcad+NOX5+ (e) transgenic mice (n=8–
10/group). 18s RNA and β-actin (42 kDa) serve as housekeeping gene and protein, 
respectively. Data are shown as mean ± SEM. *p<0.05 vs respective control Sm22+NOX5− or 
VEcad+NOX5− mice; †p<0.05 vs respective control Sm22+NOX5+ or VEcad+NOX5+ mice; 
‡p<0.05 vs respective diabetic Sm22+NOX5− or VEcad+NOX5− mice; ¶p=0.055 vs diabetic 
VEcad+NOX5− mice. C, non-diabetic control mice; D, diabetic mice 
 
Fig. 5 Gene and protein expression of MCP-1 in the kidney. (a, c, d, f) Western blots 
showing the expression of MCP-1 (25 kDa) in the renal cortex of the respective control and 
Akita diabetic Sm22+NOX5− and Sm22+NOX5+ (a) or VEcad+NOX5− and VEcad+NOX5+ (d) 
transgenic mice and quantification of the expression levels (c, f) (n=6 or 7/group). (b, e) 
Renal Mcp-1 mRNA expression in control and Akita diabetic Sm22+NOX5− and 
Sm22+NOX5+ (b) or VEcad+NOX5− and VEcad+NOX5+ (e) transgenic mice (n=8–10/group). 
18s RNA and β-actin (42 kDa) serve as housekeeping gene and protein, respectively. Data are 
shown as mean ± SEM. *p<0.05 vs respective control Sm22+NOX5− or VEcad+NOX5− mice; 
†p<0.05 vs respective control Sm22+NOX5+ or VEcad+NOX5+ mice; ‡p<0.05 vs respective 
diabetic Sm22+NOX5− or VEcad+NOX5− mice; ¶p=0.055 vs diabetic VEcad+NOX5− mice. C, 
non-diabetic control mice; D, diabetic mice 
 
Fig. 6 Gene and protein expression of TLR-4 in the kidney. (a, c, f, h) Western blots 
showing the expression of TLR-4 (120 kDa) in the renal cortex of the respective control and 
Akita diabetic Sm22+NOX5− and Sm22+NOX5+ (a) or VEcad+NOX5− and VEcad+NOX5+ (f) 
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transgenic mice and quantification of the expression levels (n=3/group) (c, h). (b, g) Gene 
expression of Tlr4 in control and Akita diabetic Sm22+NOX5− and Sm22+NOX5+ (b) or 
VEcad+NOX5− and VEcad+NOX5+ (g) transgenic mice (n=8–10/group). (d, e, i, j) 
Immunostaining of glomerular TLR-4 in control and Akita diabetic Sm22+NOX5− and 
Sm22+NOX5+ (d) or VEcad+NOX5− and VEcad+NOX5+ (i) transgenic mice and quantification 
(e, j) (n=5 or 6/group). 18s RNA and β-actin (42 kDa) serve as housekeeping gene and 
protein, respectively. Scale bar, 20 μm in all photomicrographs. Data are shown as mean ± 
SEM. *p<0.05 vs respective control Sm22+NOX5− or VEcad+NOX5− mice; †p<0.05 vs 
respective control Sm22+NOX5+ or VEcad+NOX5+ mice; ‡p<0.05 vs respective diabetic 
Sm22+NOX5−  or VEcad+NOX5− mice and ¶p=0.055 vs diabetic VEcad+NOX5− mice. C, non-
diabetic control mice; D, diabetic mice 
 
Fig. 7 Gene and protein expression of PKC-α in the kidney. (a, c, f, h) Western blots 
showing the expression of renal cortical PKC-α (83 kDa) in the renal cortex of the respective 
control and Akita diabetic Sm22+NOX5− and Sm22+NOX5+ (a) or VEcad+NOX5− and 
VEcad+NOX5+ (f) transgenic mice and quantification of the expression levels (c, h). (b, g) 
Gene expression of Pkc-α (also known as Pkca) in control and Akita diabetic Sm22+NOX5− 
and Sm22+NOX5+ (b) or VEcad+NOX5− and VEcad+NOX5+ (g) transgenic mice (n=7–
10/group). (d, e, i, j) Immunostaining of glomerular PKC-α in control and Akita diabetic 
Sm22+NOX5− and Sm22+NOX5+ (d) or VEcad+NOX5− and VEcad+NOX5+ (i) transgenic mice 
and quantification (e, j) (n=6 or 7/group). 18s RNA and β-actin (42 kDa) serve as 
housekeeping gene and protein, respectively. Scale bar, 20 μm in all photomicrographs. Data 
are shown as mean ± SEM. *p<0.05 vs respective control Sm22+NOX5− or VEcad+NOX5− 
mice; †p<0.05 vs respective control Sm22+NOX5+ or VEcad+NOX5+ mice; ‡p<0.05 vs 
respective diabetic Sm22+NOX5− or diabetic VEcad+NOX5− mice; ¶p=0.05 vs control 
Sm22+NOX5− mice. C, non-diabetic control mice; D, diabetic mice 
 
Fig. 8 Expression of NOX5 exacerbates glomerular injury in Akita diabetic mice. Periodic 
Acid–Schiff staining (a, d), mesangial area expansion (b, e) and GSI (c, f) in the respective 
wild-type control and heterozygous diabetic Sm22+NOX5− and Sm22+NOX5+ (a–c) or 
VEcad+NOX5− and VEcad+NOX5+ (d–f) transgenic Akita mice (n=8–10/group). Scale bar, 20 
μm in all photomicrographs. Data are shown as mean ± SEM. *p<0.05 vs respective control 
Sm22+NOX5− or VEcad+NOX5− mice; †p<0.05 vs respective control Sm22+NOX5+ or 
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VEcad+NOX5+ mice; ‡p<0.05 vs diabetic Sm22+NOX5− mice; ¶p=0.055 vs diabetic 
VEcad+NOX5− mice. C, non-diabetic control mice; D, diabetic mice 
 
Fig. 9 Expression of NOX5 exacerbates renal fibrosis in Akita diabetic mice. Renal gene 
expression of collagen III, fibronectin and α-SMA (a, d), immunostaining of collagen IV (b, 
e) and its quantification (c, f) in the respective control and Akita diabetic Sm22+NOX5− and 
Sm22+NOX5+ (a–c) or VEcad+NOX5− and VEcad+NOX5+ (d–f) transgenic mice (n=8–
10/group). Scale bar, 20 μm in all photomicrographs. Data are shown as mean ± SEM. 
*p<0.05 vs respective control Sm22+NOX5− or VEcad+NOX5− mice; †p<0.05 vs respective 
control Sm22+NOX5+ or VEcad+NOX5+ mice; ‡p<0.05 vs diabetic Sm22+NOX5−  or 
VEcad+NOX5− mice and p=0.056 vs diabetic VEcad+NOX5− mice. C, non-diabetic control 
mice; D, diabetic mice 
 
Fig. 10 Protein expression of HSP90 in the kidney. (a, c) Western blot showing the 
expression of HSP90 (85 kDa) in the renal cortex of the respective control and Akita diabetic 
Sm22+NOX5− and Sm22+NOX5+ (a) or VEcad+NOX5− and VEcad+NOX5+ (c) transgenic mice 
and quantification of expression levels (b, d) (n=3 or 4/group). β-actin (42 kDa) serves as 
housekeeping protein. Data are shown as mean ± SEM. †p<0.05 vs respective control 
Sm22+NOX5+ or VEcad+NOX5+ mice; ‡p<0.05 vs respective diabetic Sm22+NOX5− or 
VEcad+NOX5− mice 
 
Fig. 11 Protein expression of TRPC-6 in the kidney. (a, c) western blot showing the 
expression of TRPC-6 (106 kDa) in the renal cortex of the respective w control andAkita 
diabetic Sm22+NOX5− and Sm22+NOX5+ (a) or VEcad+NOX5− and VEcad+NOX5+ (c) 
transgenic mice and quantification of expression levels (b, d) (n=3/group). β-actin (42 kDa) 
serves as housekeeping protein. Data are shown as mean ± SEM. †p<0.05 vs respective 
control Sm22+NOX5+ or VEcad+NOX5+ mice; ‡p<0.05 vs diabetic Sm22+NOX5− mice;  
¶p=0.06 vs VEcad+NOX5− diabetic Akita mice 
 
Fig. 12 Schematic representation of the contribution of NOX5 expression in renal injury in 
diabetes via activation of inflammatory elements (TLR-4, NF-κB and MCP-1) and PKC-α   
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Table 1 Metabolic variables of Sm22+NOX5− and Sm22+NOX5+ Akita diabetic and non-
diabetic mice 
Variable Sm22+NOX5−  Sm22+NOX5+ 
 Control Diabetes   Control  Diabetes  
Body weight (g) 30±0.6 28±0.5*  31±1.0 28±0.9† 
Kidney weight/body 
weight (%) 
0.70±0.01 1.02±0.03*  0.65±0.02 1.03±0.04† 
Plasma glucose (mmol/l) 11.7±0.5 31.4±0.9*  11.4±0.7 32.1±0.8† 
HbA1c (mmol/mol) 21±0.26 80±3.1*  20±0.08 80±2.7† 
HbA1c (%) 4.1±0.02 9.5±0.3*  4.0±0.01 9.5±0.2† 
Systolic blood pressure 
(mmHg) 
107±0.6 108±1.5  106±0.7 109±0.7 
Food intake (g/day) 3.4±0.2 6.0±0.2*  3.5±0.2 6.2±0.2† 
Water intake (ml/day) 5.9±0.7 22.7±1.4*  6.9±0.5 25.7±1.2† 
Urine output (ml/day) 0.72±0.1 19.1±1.1*  1.3±0.2 19.9±1.0† 
Creatinine clearance (ml 
min−1 m−2) 
13.0±2.0 25.9±6.0*  10.3±1.3 19.1±3.0 
Albuminuria (µg/24 h) 27±2 438±152*  38±4 596±135† 
ACR (mg/mmol) 8.25±0.57 62.04±12.09
* 
 9.27±0.57 94.92±11.07†§ 
Data are shown as mean ± SEM; n=15–20/group for all variables except ACR and creatinine 
clearance (n=8–10/group) 
*p<0.05 vs non-diabetic control Sm22+NOX5− mice; †p<0.05 vs non-diabetic control 
Sm22+NOX5+ mice; §p=0.057 vs diabetic Sm22+NOX5− mice 
ACR, albumin/creatinine ratio 
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Table 2 Metabolic variables in VEcad+NOX5− and VEcad+NOX5+ Akita diabetic and non-
diabetic mice 
Variable VEcad+NOX5−  VEcad+NOX5+ 
 Control Diabetes  Control Diabetes 
Body weight (g) 31±0.5 29±0.5*  32±0.9 30±0.5† 
Kidney weight/body 
weight (%) 
0.63±0.04 1.0±0.04*  0.67±0.02 1.03±0.04† 
Plasma glucose (mmol/l) 11.0±0.4 32.1±0.9*  11.7±0.3 31.5±0.9† 
HbA1c (mmol/mol) 22±0.70 84±1.2*  20±0.27 78±2.4† 
HbA1c (%) 4.2±0.1 9.8±0.2*  4.0±0.03 9.3±0.2† 
Systolic blood pressure 
(mmHg) 
106±0.8 107±0.6  106±0.9 108±0.8 
Food intake (g/day) 3.1±0.3 5.9±0.2*  3.1±0.2 5.9±0.2† 
Water intake (ml/day) 3.9±0.6 22.9±1.5*  4.5±1.0 23.0 ± 0.8† 
Urine output (ml/day) 0.84±0.1 19.6±0.9*  2.0±0.8 19.1±0.7† 
Creatinine clearance (ml 
min−1 m−2) 
17.4±3.9 42.3±10.7*  19.7±6.5 31.2±6.5 
Albuminuria (µg/24h) 31±3 770±98*  32±3 1192±194†‡ 
ACR (mg/mmol) 8.93±0.57 93.9±14.58*  9.61±1.02 153.68±22.26
†‡ 
Data are shown as mean ± SEM; n=18–20/group for all variables except ACR and creatinine 
clearance (n=8–10/group) 
*p<0.05 vs non-diabetic control VEcad+NOX5− mice; †p<0.05 vs non-diabetic control 
VEcad+NOX5+ mice; ‡p<0.05 vs diabetic VEcad+NOX5− mice 
ACR, albumin/creatinine ratio 
 
 
